Delivery of adjuvant sequential dose-dense FEC–Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequenceH. Wildiers, R. Paridaens, Paul M. Clément et al.|Breast Cancer Research and Treatment|2008Cited by 30
Locally advanced breast cancers: the EUSOMA experiencePeter A. van Dam, Serena Scomersi, Mariano Tomatis et al.|European Journal of Surgical Oncology|2025Cited by 1